• Founded: 2014
  • Location: Rockville, MD
  • Employee range: 11 - 50
  • Clinical stage: Clin2
  • Therapy area: NSCLC
  • Drug types: ONC, INF, VAC, NEU, TOX, IMM
  • Lead product: NT-I7 (multiple partners)
  • Product link:
  • Funding: not disclosed

job board

Short description:


Drug notes:

Also 10 additional trials Clin1/Clin2 multiple cancers, Clin1 COVID-19, Clin1 vaccine adjuvant (ODD), Clin1 multifocal leukoencephalopathy; Clin0 idiopathic CD4 lymphocytopenia (ODD), Clin0 acute radiation syndrome

Long description:

NeoImmuneTech is a clinical-stage biopharmaceutical company creating innovative T cell therapies that harness the immune system to target and destroy cancer cells. They are dedicated to discovering and developing novel immunotherapeutics to improve therapeutic options in immuno-oncology and infectious diseases. Their therapeutic approach modifies T cells response by inducing their activation, enhancing their response, and facilitating engagement with target cancer cells. Their heterodimer Fc drug development platform, called NEOBASE, allows for rapid development of multi-specific antibodies with increased stability and efficacy. This platform is used to enhance the body’s immune response through the improvement of protein function.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy